Ashley Lamb, DO
Orthopaedic Surgery · Los Angeles, CANPI 1538519608
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (38.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Stryker at 41.0% of the total. Reporting peaked in 2022 at $5,021 and has fallen 63.0% since, to $1,857 in 2025.
Across 89 payments — averaging $161.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$6K
- Micromed Inc$4K
- Arthrex$3K
- Zimmer Biomet$798
- Peerless Surgical Inc.$201
- Bioventus LLC$166
- plus $247 from 4 others
What the payments were for
- Grants$2502%
- Travel & lodging$4,86334%
- Food & beverage$3,70026%
- Education$5,58339%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 57 | $5,905 |
| Micromed Inc | 3 | $4,383 |
| Arthrex | 10 | $2,696 |
| Zimmer Biomet | 10 | $798 |
| Peerless Surgical Inc. | 2 | $201 |
| Bioventus LLC | 3 | $166 |
| Medline Industries LP | 1 | $136 |
| Highridge Medical LLC | 1 | $41 |
| Pfizer | 1 | $40 |
| Amgen | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,396 in reported general payments places this provider in the 75th percentile of 1,808 orthopaedic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 25 | $574 |
| Diclofenac Sodium | 18 | $314 |
| Meloxicam | 54 | $104 |
| Ibuprofen | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Los Angeles
- Kelly VinceLos Angeles$9.6M
- Jay LiebermanLos Angeles$4.8M
- Thomas SchmalzriedLos Angeles$4M
- David SkaggsLos Angeles$2.6M
- David ThordarsonLos Angeles$2.5M
- Edward McPhersonLos Angeles$1.2M
- Daniel AllisonLos Angeles$1.1M
- Justin SalimanLos Angeles$912K
- Charles MoonLos Angeles$760K
- Andrew SpitzerLos Angeles$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.